FierceBiotechFierceBioResearcherFierceVaccinesFiercePharma   FierceHealthcare
Syndicate content

controversy news from FierceBiotech

News

In Austin, VC is booming for biotechs

Further evidence of Texas' growing power in the biotech industry: the Austin Business Journal reports that in recent months, central Texas-based life science outfits have attracted about $500 million... Read more...

Cepheid cashes in on MRSA trends--for now

With cases of antibiotic-resistant MRSA multiplying and fear of the superbug rising, Cepheid... Read more...

Experts debate FDA signals on cancer drug approval

When is a cancer therapy good enough? The Boston Globe examines answers to that question following the recent controversy over the FDA's decisions in the field. Most recently, Avastin gained a new... Read more...

Financial conflicts raise questions over trial results

A bubbling controversy over a clinical trial for a new device to cure back pain is being used to highlight how conflicts arise when researchers stand to gain financially from an experimental... Read more...

ALSO NOTED: Cardiome awaits FDA decision; Congress to investigate Vytorin scandal; and much more...

> Cardiome is awaiting a critical FDA decision on its drug vernakalant. Report > It seems that many black U.S. residents... Read more...

Human embryo clones unveiled by CA scientists

Scientists in California made embryo clones of two men, a step toward developing new stem cells for therapeutic purposes. But a number of experts quickly noted that cloned embryos of humans have been... Read more...

Foundation draws charges of industry influence

The Reagan-Udall Foundation was created by Congress to ramp up innovation in drug science, help... Read more...

Mass. Bio members distraught over new controversy

With a fresh controversy swirling around newly appointed Executive Director Robert Coughlin, the Massachusetts Biotechnology Council is being hit with criticism from its own members concerned that... Read more...

Texas'$3B cancer program draws controversy

Texas voters will have the final say on a proposed $3 billion effort to support cancer research over 10 years inside the Lone Star state. This is the brainchild of the governor, who's clearly... Read more...

Gilead touts Phase III Hep B results

Gilead is reporting that a Phase III trial of its HIV drug Viread was more effective at reducing amounts of the hepatitis B virus than the company's other antiviral drug, Hepsera. At 48 weeks, 66.5 percent receiving Viread had a complete response compared to 12.2 percent in the Hepsera arm. "The preliminary data observed in both Phase III trials evaluating Viread as a potential treatment option for chronic hepatitis B are very encouraging," said Franck Rousseau, MD, Vice President, …

... Read more...

Get more controversy coverage at: